Lifevantage (LFVN) Competitors $13.39 +0.31 (+2.37%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$13.36 -0.03 (-0.19%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. CDXC, XNCR, KALV, EOLS, SANA, UPB, SAGE, ALT, TNGX, and KROSShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include ChromaDex (CDXC), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors ChromaDex Xencor KalVista Pharmaceuticals Evolus Sana Biotechnology Upstream Bio Sage Therapeutics Altimmune Tango Therapeutics Keros Therapeutics Lifevantage (NASDAQ:LFVN) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk. Do analysts rate LFVN or CDXC? Lifevantage currently has a consensus price target of $30.50, indicating a potential upside of 127.78%. ChromaDex has a consensus price target of $9.03, indicating a potential upside of 0.00%. Given Lifevantage's higher possible upside, equities research analysts plainly believe Lifevantage is more favorable than ChromaDex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ChromaDex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, LFVN or CDXC? Lifevantage has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Which has better earnings & valuation, LFVN or CDXC? Lifevantage has higher revenue and earnings than ChromaDex. ChromaDex is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$200.16M0.84$2.94M$0.6919.41ChromaDex$99.60M0.00-$4.94M$0.10N/A Is LFVN or CDXC more profitable? Lifevantage has a net margin of 4.12% compared to ChromaDex's net margin of 1.62%. Lifevantage's return on equity of 34.67% beat ChromaDex's return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.12% 34.67% 15.24% ChromaDex 1.62%4.85%2.70% Does the media favor LFVN or CDXC? In the previous week, Lifevantage had 2 more articles in the media than ChromaDex. MarketBeat recorded 2 mentions for Lifevantage and 0 mentions for ChromaDex. Lifevantage's average media sentiment score of 0.75 beat ChromaDex's score of 0.00 indicating that Lifevantage is being referred to more favorably in the media. Company Overall Sentiment Lifevantage Positive ChromaDex Neutral Do institutionals and insiders have more ownership in LFVN or CDXC? 35.3% of Lifevantage shares are held by institutional investors. Comparatively, 15.4% of ChromaDex shares are held by institutional investors. 20.7% of Lifevantage shares are held by insiders. Comparatively, 9.6% of ChromaDex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryLifevantage beats ChromaDex on 11 of the 14 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$164.65M$15.64B$5.48B$8.94BDividend Yield1.38%1.45%5.38%4.12%P/E Ratio19.4118.7226.2219.74Price / Sales0.842.31394.92109.12Price / Cash14.8316.7936.4957.06Price / Book6.533.817.915.37Net Income$2.94M$430.42M$3.15B$248.34M7 Day Performance6.35%2.86%0.75%1.67%1 Month Performance7.55%2.68%3.46%4.56%1 Year Performance113.90%20.24%34.60%18.42% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage4.0648 of 5 stars$13.39+2.4%$30.50+127.8%+112.9%$164.65M$200.16M19.41260CDXCChromaDex3.1692 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.0305 of 5 stars$8.41-1.5%$28.00+232.9%-57.6%$607.80M$110.49M-2.75280KALVKalVista Pharmaceuticals4.2515 of 5 stars$11.93-1.8%$24.83+108.2%-2.5%$604.04MN/A-3.21100EOLSEvolus4.0771 of 5 stars$9.38+1.1%$23.75+153.2%-17.0%$598.33M$266.27M-10.54170Positive NewsSANASana Biotechnology2.5402 of 5 stars$2.60-0.4%$10.80+315.4%-48.3%$588.49MN/A-2.95380High Trading VolumeUPBUpstream Bio1.8568 of 5 stars$10.72-1.5%$56.50+427.1%N/A$585.28M$2.37M0.0038SAGESage Therapeutics3.2066 of 5 stars$9.30flat$8.93-3.9%-17.7%$582.37M$41.24M-1.60690ALTAltimmune2.2981 of 5 stars$6.99-0.6%$19.00+171.8%-41.3%$570.18M$20K-5.5550TNGXTango Therapeutics2.2475 of 5 stars$5.32+3.1%$12.20+129.3%-39.6%$559.31M$42.07M-4.3690Analyst RevisionKROSKeros Therapeutics4.1385 of 5 stars$13.76+2.0%$30.56+122.1%-69.5%$547.90M$3.55M-76.44100 Related Companies and Tools Related Companies ChromaDex Competitors Xencor Competitors KalVista Pharmaceuticals Competitors Evolus Competitors Sana Biotechnology Competitors Upstream Bio Competitors Sage Therapeutics Competitors Altimmune Competitors Tango Therapeutics Competitors Keros Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
